EUCTR2017-001225-41-ES进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 738
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For Substudy 1:
- •- Participant who receive double-blind treatment in Study M14- 431 or Study M14-433 and achieve clinical response.
- •- Participant completes Week 12 or Week 24 study procedures
- •For Substudy 2:
- •- Participant completes Substudy 2
- •- Participant who receive open-label upadacitinib Dose B in Study M14-431 and achieve clinical response.
- •- Participant completes study procedures in the parent study/substudy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 731
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 37
排除标准
- •For Sub-studies 1 and 2:
- •- Participant is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
- •- Participant who has a known hypersensitivity to upadacitinib or its excipients, or had an adverse event during Study M14-431 or Substudy 1 of Study M14-430 that in the investigator's judgment makes the subject unsuitable for this study.
- •- Participant with any active or chronic recurring infections based on the investigator's assessment that makes the subject an unsuitable candidate for the study. Subjects with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection treatment has been completed and the infection is cured, based on the investigator's assessment.
- •- Participants with high grade colonic dysplasia or malignancy diagnosed at the endoscopy performed at the final visit of Study M14-431 (Week 24) or Substudy 1 of Study M14-430 (Week 40).
研究者
相似试验
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433Crohn's Disease (CD)MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-001225-41-IEAbbVie Deutschland GmbH & Co. KG747
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433EUCTR2017-001225-41-GBAbbVie Deutschland GmbH & Co. KG738
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with MenopauseGenerally healthy, postmenopausal women of age 40 to 65 seeking treatment for hot flushes with last natural menstrual period (LNMP) completed at least 12 months prior to screening (if LNMP is uncertain, the medical monitor or designee may approve a follicle-stimulating hormone [FSH] levelFSH level > 40 mIU/mL will allow enrollment).EUCTR2004-005022-45-HUWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development465
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, CrossoverStudy to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of AcuteMigraine in Patients With Stable Vascular Disease. - NDPatients With Stable Vascular Disease and Acute Migraine AttacksMedDRA version: 9.1Level: LLTClassification code 10027599Term: MigraineEUCTR2007-007723-40-ITMERCK SHARP DOHME ITALIA S.P.A.400
进行中（未招募）
1 期
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433EUCTR2017-001225-41-BEAbbVie Deutschland GmbH & Co. KG906